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BASELINE COMPARISON OF PATIENTS WITH
SCHIZOPHRENIA USING OLANZAPINE,
RISPERIDONE AND TYPICAL ANTIPSYCHOTICS
IN CALIFORNIA MEDICAID PROGRAM
Mulani P1, Gibson PJ2, McCombs J1
1University of Southern California, Los Angeles, CA, USA;
2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To assess the demographic, diagnostic and
cost differences at baseline among Medi-Cal patients with
schizophrenia using olanzapine, risperidone, or typical
antipsychotics.
METHODS: Ambulatory patients with schizophrenia,
who initiated antipsychotic drug therapy on olanzapine,
risperidone or typical antipsychotics, after a break of
more than 30 days from their previous antipsychotics,
were identiﬁed. Of these, patients with data available 
for at least six months prior to and 12 months following
the initiation date of these medications during March
1998-August 2001 were included. Baseline demographic,
diagnostic and cost variables were compared among these
three groups.
RESULTS: The ﬁnal sample comprised of 8022, 4909,
4867, olanzapine, risperidone and typical (O;R;T) patient
episodes respectively. The episodes for which typical
antipsychotics were initiated had the highest total costs
in the six months prior to drug initiation (mean (SE): O
= $4,224 (11,219); R = $4,339 (11,217); T = $5,403
(14,786); p < 0.0001). Patients initiated on olanzapine
had been more treatment resistant, as indicated by 
differences in use of more than two antipsychotics 
previously (O = 42.97%; R = 37.10%; T = 40.13%; p <
0.0001), prior clozapine use (O = 1.11%; R = 0.71%; T
= 1.07%; p < 0.07), prior use of depot antipsychotics (O
= 3.96%; R = 2.55%; T = 2.16%; p < 0.0001) and dose
of prior antipsychotic (mean chlorpromazine equivalents
(SE): O = 228.1 (662); R = 161.2 (494); T = 130.5 (474);
p < 0.0001). Patients with episodes treated with typical
antipsychotics had a higher proportion of comorbidities
including muskoskeletal system disorders, anxiety 
disorders, and circulatory system diseases. Olanzapine
had relatively few older and younger initiators (age <20
or age >65), compared to risperidone (O = 13.67%; R =
24.69%; T = 18.90%; p < 0.0001).
CONCLUSIONS: Signiﬁcant cost, demographic and
diagnostic differences at baseline existed among 
patients initiating risperidone, olanzapine, and typical
antipsychotics. Speciﬁcally, olanzapine was used for 
more treatment resistant patients with schizophrenia.
Non-randomized studies comparing treatment and cost
outcomes for these medications need to account for the
differences.
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THE IMPACT OF SECOND-GENERATION
ANTIPSYCHOTICS IN BIPOLAR PATIENTS IN
THE CALIFORNIA MEDICAID PROGRAM
Sterling KL, McCombs J
University of Southern California, Los Angeles, CA, USA
The California Medicaid program added second-
generation antipsychotic medications to its formulary in
October 1997.
OBJECTIVE: To investigate the impact of the formulary
expansion on antipsychotic drug selection. STUDY 
POPULATION: 52,389 antipsychotic-initiated patient
treatment episodes were separated into three groups, new:
no previous drug therapy history, restarters: restarted
drug therapy while not on active therapy, and aug-
menters: started a new drug while on active therapy.
METHODS: Time trend analysis was performed to deter-
mine the changes in the number of overall treatment
episodes initiated with an antipsychotic within each of the
three subgroups. Multivariate logistic regression models
of the selection of drug therapy were estimated separately
for the three subgroups. Independent variables included
patient demographics, prior use of services, and diagnos-
tic proﬁle.
RESULTS: The formulary expansion immediately but
temporarily increased the total number of restarter and
augmenter episodes, with a less apparent increase in the
total number of new episodes (access effect). Once at
steady state level within all three subgroups, second-
generation antipsychotics accounted for approximately
two-thirds of antipsychotic treated episodes. The formu-
lary expansion changed the clinical parameters that inﬂu-
enced the selection of antipsychotic therapy. Factors that
correlate with the use of second-generation antipsychotics
in the pre-period appear to have been attenuated by the
formulary expansion. The formulary expansion increased
access to the second-generation antipsychotics for minori-
ties, HIV+ persons, persons with history of alcohol abuse,
individuals in the long term care setting, and in urban
counties. Access to the second-generation antipsychotics
was less dependent on psychiatric hospital visits, visits to
psychiatrists, and having a previous diagnosis of schizo-
phrenia or depression in the medical history.
CONCLUSION: Future research should explore the
impact of the formulary expansion on the cost and
achievement of drug therapy outcomes of treating
patients with bipolar disorder, with consideration of
potential treatment selection bias.
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REDUCTION IN LONG-ACTING
BENZODIAZEPINE THERAPY AND ASSOCIATED
FRACTURES IN ELDERLY MEDICAID PATIENTS
Dodd MA, Shah BM, Gupchup GV,Anderson JR
The University of New Mexico, Albuquerque, NM, USA
OBJECTIVES: The objectives of this study were to
encourage the replacement of long-acting benzodi-
